IP News & Updates
Novartis-Abogen mRNA Deal: Why US Rules Do Not Block It and What It Means for US Biotech
The Novartis-Abogen deal, announced on 2 October 2026, gives Novartis worldwide rights to ABO2203, an experimental mRNA medicine for autoimmune disease developed…
Read Full Article